<http://webisa.webdatacommons.org/22025802>	<http://www.w3.org/ns/prov#value>	"This is the first regulatory approval worldwide for ALPROLIX, which is currently under review by regulatory authorities in several other countries, including the United States, Australia and Japan.Health Canada's approval of ALPROLIX marks the first significant treatment advance in hemophilia B in 17 years, and reinforces our commitment to developing innovative therapies that help address the cri" .
<http://webisa.webdatacommons.org/22025802>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<biospace.com> .
<http://webisa.webdatacommons.org/prov/442366997>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/22025802> .
<http://webisa.webdatacommons.org/22025802>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/25185589>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/22025802> .